Literature DB >> 26297039

Overexpression and mutation as a genetic mechanism of fluconazole resistance in Candida albicans isolated from human immunodeficiency virus patients in Indonesia.

Yeva Rosana1, Andi Yasmon1, Delly Chipta Lestari1.   

Abstract

Fluconazole is the standard treatment for oropharyngeal candidiasis, which is the third most common opportunistic infection in human immunodeficiency virus (HIV)/AIDS patients in Indonesia. Overuse of this drug could lead to the emergence of resistance. The objective of this study was to analyse the role of ERG11, CDR1, CDR2 and MDR1 gene overexpression and mutations in the ERG11 gene as a genetic mechanism of fluconazole resistance in Candida albicans isolated from HIV patients in Indonesia. Overexpression of ERG11, CDR1, CDR2 and MDR1 was analysed by real-time reverse transcription PCR, while ERG11 gene mutation analysis was performed using sequencing methods. Seventeen isolates out of 92 strains of C. albicans isolated from 108 HIV patients were found to be resistant to azole antifungals. The highest gene overexpression of ERG11 was found in C. albicans resistant to single fluconazole, while the highest gene overexpression of CDR2 was detected in all isolates of C. albicans resistant to multiple azoles. Amino acid substitutions were observed at six positions, i.e. D116E, D153E, I261V, E266D, V437I and V488I. The amino acid substitution I261V was identified in this study and was probably associated with fluconazole resistance. The combination of overexpression of CDR2 and ERG11 and mutation in the ERG11 gene was found to be a genetic mechanism of fluconazole resistance in C. albicans isolated from HIV patients in Indonesia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26297039     DOI: 10.1099/jmm.0.000123

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

Review 1.  Comparative Efficacy and Safety of Antifungal Agents in the Prophylaxis of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis.

Authors:  Shamala Gopal Rajadurai; Mari Kannan Maharajan; Sajesh K Veettil; Divya Gopinath
Journal:  Life (Basel)       Date:  2022-03-31

2.  Investigation of fluconazole susceptibility to Candida albicans by MALDI-TOF MS and real-time PCR for CDR1, CDR2, MDR1 and ERG11.

Authors:  Chanika Maenchantrarath; Pradchama Khumdee; Seksun Samosornsuk; Narissara Mungkornkaew; Worada Samosornsuk
Journal:  BMC Microbiol       Date:  2022-06-10       Impact factor: 4.465

3.  In vitro activity of econazole in comparison with three common antifungal agents against clinical Candida strains isolated from superficial infections.

Authors:  M Abastabar; T Shokohi; R Rouhi Kord; H Badali; S J Hashemi; Z Ghasemi; A Ghojoghi; N Baghi; M Abdollahi; S Hosseinpoor; N Rahimi; Z Seifi; S Gholami; I Haghani; M R Jabari; A Pagheh
Journal:  Curr Med Mycol       Date:  2015-12

4.  A pre-therapeutic coating for medical devices that prevents the attachment of Candida albicans.

Authors:  Diego Vargas-Blanco; Aung Lynn; Jonah Rosch; Rony Noreldin; Anthony Salerni; Christopher Lambert; Reeta P Rao
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-05-19       Impact factor: 3.944

Review 5.  Oropharyngeal Candidosis in HIV-Infected Patients-An Update.

Authors:  Shankargouda Patil; Barnali Majumdar; Sachin C Sarode; Gargi S Sarode; Kamran H Awan
Journal:  Front Microbiol       Date:  2018-05-15       Impact factor: 5.640

6.  A Crucial Role for Ergosterol in Plasma Membrane Composition, Localisation, and Activity of Cdr1p and H+-ATPase in Candida albicans.

Authors:  Jakub Suchodolski; Jakub Muraszko; Przemysław Bernat; Anna Krasowska
Journal:  Microorganisms       Date:  2019-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.